{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:50:21Z","timestamp":1787903421126,"version":"build-2784847793"},"reference-count":14,"publisher":"The Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Context: Therapeutic use of GHRH to enhance GH secretion is limited by its short duration of action.<\/jats:p>\n                  <jats:p>Objective: The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting GHRH analog.<\/jats:p>\n                  <jats:p>Design: The study design was two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 d.<\/jats:p>\n                  <jats:p>Setting: The study was performed at two investigational sites.<\/jats:p>\n                  <jats:p>Participants: Healthy subjects, ages 21\u201361 yr, were studied.<\/jats:p>\n                  <jats:p>Interventions: CJC-1295 or placebo was administered sc in one of four ascending single doses in the first study and in two or three weekly or biweekly doses in the second study.<\/jats:p>\n                  <jats:p>Main Outcome Measures: The main outcome measures were peak concentrations and area under the curve of GH and IGF-I; standard pharmacokinetic parameters were used for CJC-1295.<\/jats:p>\n                  <jats:p>Results: After a single injection of CJC-1295, there were dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9\u201311 d. The estimated half-life of CJC-1295 was 5.8\u20138.1 d. After multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 d. No serious adverse reactions were reported.<\/jats:p>\n                  <jats:p>Conclusions: Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 \u03bcg\/kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC-1295 as a therapeutic agent.<\/jats:p>","DOI":"10.1210\/jc.2005-1536","type":"journal-article","created":{"date-parts":[[2006,2,6]],"date-time":"2006-02-06T19:29:21Z","timestamp":1139254161000},"page":"799-805","source":"Crossref","is-referenced-by-count":46,"title":["Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults"],"prefix":"10.1210","volume":"91","author":[{"given":"Sam L.","family":"Teichman","sequence":"first","affiliation":[{"name":"WinPharm Associates (S.L.T., A.N.), Alamo, California 94507"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Neale","sequence":"additional","affiliation":[{"name":"WinPharm Associates (S.L.T., A.N.), Alamo, California 94507"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Lawrence","sequence":"additional","affiliation":[{"name":"ConjuChem, Inc. (B.L., C.G., J.-P.C.), Montre\u0301al, Que\u0301be\u0301c, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Gagnon","sequence":"additional","affiliation":[{"name":"ConjuChem, Inc. (B.L., C.G., J.-P.C.), Montre\u0301al, Que\u0301be\u0301c, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Castaigne","sequence":"additional","affiliation":[{"name":"ConjuChem, Inc. (B.L., C.G., J.-P.C.), Montre\u0301al, Que\u0301be\u0301c, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Frohman","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Department of Medicine, University of Illinois (L.A.F.), Chicago, Illinois 60612"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071616570035800_R1","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1210\/jcem-18-8-901","article-title":"Treatment of a pituitary dwarf with human growth hormone.","volume":"18","author":"Raben","year":"1958","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616570035800_R2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1651-2227.1989.tb17180.x","article-title":"Use of continuous subcutaneous growth hormone-releasing hormone (GHRH (1\u201329)NH2) infusions to augment growth hormone secretion and to promote growth.","volume":"78","author":"Brain","year":"1989","journal-title":"Acta Paediatr Scand"},{"key":"2020071616570035800_R3","first-page":"1189","article-title":"Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.","volume":"81","author":"Thorner","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616570035800_R4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jama.292.2.210","article-title":"Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial.","volume":"292","author":"Koutkia","year":"2004","journal-title":"JAMA"},{"key":"2020071616570035800_R5","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1172\/JCI112679","article-title":"Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive, N-terminally cleaved product.","volume":"78","author":"Frohman","year":"1986","journal-title":"J Clin Invest"},{"key":"2020071616570035800_R6","first-page":"3301","article-title":"Appraisal of growth hormone (GH) secretion: evaluation of a composite pharmacokinetic model that discriminates multiple components of GH input.","volume":"84","author":"Bright","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616570035800_R7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1530\/eje.1.01965","article-title":"Polyethylene glycol-conugated growth hormone-releasing hormone is long-acting and stimulates GH in healthy young and elderly subjects.","volume":"153","author":"Munafo","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"2020071616570035800_R8","first-page":"491","author":"Benquet","year":"2004"},{"key":"2020071616570035800_R9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1172\/JCI111424","article-title":"Plasma growth hormone responses to constant infusions of human pancreatic growth hormone releasing factor: intermittent secretion or response attenuation.","volume":"74","author":"Webb","year":"1984","journal-title":"J Clin Invest"},{"key":"2020071616570035800_R10","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1172\/JCI111864","article-title":"Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (l-40).","volume":"75","author":"Vance","year":"1985","journal-title":"J Clin Invest"},{"key":"2020071616570035800_R11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2362.2004.01380.x","article-title":"Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study.","volume":"34","author":"Andersen","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"2020071616570035800_R12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00042560-200208010-00002","article-title":"Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection.","volume":"30","author":"Engelson","year":"2002","journal-title":"J Acquired Immune Defic Syndr"},{"key":"2020071616570035800_R13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00001432-200502000-00004","article-title":"Use of recombinant human growth hormone in HIV-associated lipodystrophy.","volume":"18","author":"Burgess","year":"2005","journal-title":"Curr Opin Infect Dis"},{"key":"2020071616570035800_R14","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/01.aids.0000180099.35146.30","article-title":"A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.","volume":"19","author":"Falutz","year":"2005","journal-title":"AIDS"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/91\/3\/799\/10779632\/jcem0799.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/91\/3\/799\/10779632\/jcem0799.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T23:28:21Z","timestamp":1594942101000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/91\/3\/799\/2843281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,1]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2005-1536","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,1]]}}}